Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Conditions:   HER2-positive Breast Cancer;   HER2 Gene Mutation;   HER-2 Gene Amplification;   HER2 Positive Gastric Cancer;   Salivary Gland Cancer;   Salivary Gland Tumor;   Salivary Gland Carcinoma;   Salivary Gland Neoplasms;   Lung Cancer;   Colo-rectal Cancer;   Rare Diseases;   Solid Tumor;   Recurrent Gastric Cancer;   Recurrent Colon Cancer;   Recurrent Breast Cancer;   Head and Neck Cancer;   Head and Neck Carcinoma;   Bladder Cancer;   Cervical Cancer;   Liver Cancer;   Bile Duct Cancer;   Urologic Cancer;   Pancreatic Cancer;   Prostate Cancer;   Recurrent Prostate Cancer;   Rectal Cancer;   Recurrent Ovarian Carcinoma;   Recurrent Renal Cell Cancer;   Rectal Cancer Stage II;   Rectal Cancer Stage I;   Rectal Cancer Stage III;   Skin Cancer;   Mouth Cancer;   Lip Cancer Stage I;   Tongue Cancer;   Breast Neoplasm Malignant Primary;   Larynx Cancer;   Tonsil Cancer;   Palate Cancer;   Mucoepidermoid Carcinoma;   Primary Peritoneal Carcinoma;   Mucinous Adenocarcinoma Gastric;   Mucinous Breast Cancer Recurrent
Intervention:   Drug: A166
Sponsor:   Klus Pharma Inc.
Recruiting

https://ift.tt/2OiLuBK